INTRODUCTION
============

*Panax ginseng Meyer* commonly known as Korean ginseng, which belongs to the *Araliaceae* family. Ginseng has bioactive effects on human health; it is widely used to treat immune dysfunction, liver dysfunction, renal deficiency, and blood vesselrelated diseases of the heart and brain. The human life span has dramatically increased in recent years, and aging is associated with several diseases. Osteoporosis is a widespread disease that is especially serious in countries with a large population of older adults. In 2004, the World Health Organization reported that \~75 million people were affected by osteoporosis ([@b25-molce-39-12-855]). Studies have examined the effects of ginseng-containing herbal extracts from ginseng and ginseng-related plants such as Siberian ginseng on pathologic bone remodeling ([@b11-molce-39-12-855]; [@b12-molce-39-12-855]; [@b18-molce-39-12-855]). Little is known, however, about the effects of ginseng on bone health ([@b15-molce-39-12-855]).

In vertebrates, bone health is maintained by bone formation and resorption. Many bone disorders result from an imbalance between these two mechanisms ([@b5-molce-39-12-855]). Osteoblasts originate from mesenchymal stem cells, whereas osteoclasts are formed from macrophages derived from hematopoietic stem cells. Osteoclasts are multinucleated cells formed by fusion of mononuclear macrophages ([@b3-molce-39-12-855]). Osteoblast cells affect osteoclast differentiation through macrophage colony-stimulating factor-1 (MCSF-1) and receptor activator of NF-κB ligand (RANKL). Both are sufficient and necessary for osteoclast differentiation ([@b10-molce-39-12-855]; [@b21-molce-39-12-855]; [@b20-molce-39-12-855]). MCSF-1 enhances osteoclast proliferation during RANKL-induced osteoclasts generation ([@b1-molce-39-12-855]). The osteoclast-activating transcription factors c-Fos and NFATc1 are also expressed by RANKL, which leads to expression of osteoclast associated receptor (OSCAR), tartrate-resistant acid phosphatase (TRAP), and other proteins ([@b22-molce-39-12-855]).

Osteoporosis weakens bones, increasing risk of fracture. Osteoporosis is classified into two types, depending on the cause: estrogen-dependent osteoporosis occurs mainly in postmenopausal woman, and age-dependent osteoporosis occurs in people older than 70 years ([@b14-molce-39-12-855]). The effects of herbal products and traditional foods on enhanced mineral accumulation in bones and maximization of bone mass in premenopausal and postmenopausal women have been studied. Traditional herbal medicines and natural materials have been investigated as possible cures for osteoporosis because of their inhibition of osteoclast differentiation with few side effects ([@b16-molce-39-12-855]). The effects of individual components of ginseng extract on osteoporosis have been examined. Ginsenosides Rb1, Rb2, and Rg3 affect osteoclasts that influence bone homeostasis ([@b4-molce-39-12-855]; [@b7-molce-39-12-855]; [@b19-molce-39-12-855]).

Here, we used a zebrafish scale system to evaluate if ginseng and its bioactive components contributed to bone homeostasis. A major ginsenoside of aqueous ginseng extract, ginsenoside Re, exhibited novel effects in inhibiting osteoclast differentiation.

MATERIALS AND METHODS
=====================

Reagents
--------

Culture media, fetal bovine serum, and antibiotics were from Invitrogen (USA), while standard ginsenosides (including Re), anti-*β*-actin antibody, and TRAP-staining solution were from Sigma (USA). Recombinant macrophage colony stimulating factor (MCSF) was from PeproTech EC (UK). Anti-c-Fos and anti-NFATc1 were from Santa Cruz Biotechnology, Inc. (USA). Recombinant GST-RANKL was purified from an *Escherichia coli* expression system.

Preparation of aqueous ginseng extract
--------------------------------------

Aqueous ginseng extract was from the *National Agricultural Cooperative Federation* in Chungbuk, Republic of Korea. To mimic intake conditions for traditional oriental herbs, we used a previously described water extraction process ([@b13-molce-39-12-855]).

Differentiation of mouse bone marrow-derived macrophages and osteoclasts
------------------------------------------------------------------------

Bone marrow-derived macrophages (BMMs) were obtained from femurs and tibias of 6-week-old ICR mice as described previously ([@b6-molce-39-12-855]). To generate osteoclasts, BMMs (5 × 10^4^ cells/well) were incubated with MCSF (30 ng/ml) and RANKL (25 ng/ml) in 48-well (1 ml/well) tissue culture dishes with or without ginsenoside Re or ginseng extract. Cells were fixed with 10% formalin for 10 min and washed 4 times with PBS plus 0.1% Triton X-100 (PBST). Cells were incubated for a few hours in TRAP staining solution (Sigma-Aldrich).

Western blots
-------------

Cells were lysed in lysis buffer \[PBS plus 0.5% NP-40, 0.5 mM Na~3~VO~4~, 20 mM *p*-Nitrophenyl Phosphate (PNPP)\]. Equal amounts of lysate (30 μg) were separated by 8% to 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to PVDF membranes. The resulting membranes were immunoblotted with the indicated antibodies.

Experimental animals and treatments
-----------------------------------

All experimental procedures complied with the act on life ethics and safety of the Ministry of Health and Welfare of South Korea. Wild-type adult zebrafish were maintained at 27.0°C ± 1.0°C under light conditions of 14 h light and 10 h dark. Before starting the experiments, the weight of zebrafish more than 350 mg (similar in length) were maintained for 14 days in the same cage. To induce bone loss from fish scales, we reduced the feeding amount of food by 20%. Ten zebrafish per each group were separated individually in standard cages. For 7 days, the fish were raised without feeding in the presence or absence of ginsenoside Re and other 28 days, the fish were fed 2 ml (20%) of artemia one time a day in water, after 1hr the water was replaced to half volume of fresh water with or without of ginsenoside Re every day to maintain optimal water condition. 35 days later, the fish were anaesthetized with 0.01% tricaine methanesulfonate (Sigma) before scale collection; the scales were carefully removed from either side of the body under a stereomicroscope (KL300, Leica, Germany) using forceps.

Cell viability assays
---------------------

Cell cytotoxicity assays were performed as described previously ([@b6-molce-39-12-855]). Cells were cultured with or without aqueous ginseng extract (0--100 μg/ml) or ginsenoside Re (0--10 μM) for 48 h. After 1 h of Cell Counting Kit -- 8 (CCK-8) treatment (10 μl), plates were analyzed at 450 nm (650 nm reference) using a 96-well plate recorder (Molecular Devices, USA).

TRAP staining and activity assays
---------------------------------

Multinucleated osteoclasts were treated with 10% formalin for 10 min and ethanol/acetone (50%/50%) for 1 min for fixation and then stained with TRAP staining solution (Sigma-Aldrich). TRAP-positive multinucleated cells were photographed under a microscope (Olympus Optical Co. Ltd., Japan). To measure TRAP activity, cells were fixed with 10% formalin for 10 min and 95% ethanol for 1 min and then incubated with 100 μl reaction buffer (50 mM citric acid, pH 4.6, 10 mM sodium tartrate, 5 mM PNPP). After 1 h, 30 μl was transferred to a new plate containing an equal volume of stopping buffer (0.1 N NaOH). Absorbance was measured at 410 nm. TRAP activity was presented as a percentage of the control.

RNA preparation and RNA quantitation by RT-PCR
----------------------------------------------

RNA preparation and cDNA synthesis were performed as described previously ([@b6-molce-39-12-855]). Real-time polymerase chain reaction (PCR) used a CFX96™ Real-time system with SYBR FAST KAPA iCycler qPCR kit under the following conditions: 40 cycles of denaturation at 95°C (15 s) and amplification at 60°C (1 min). All reactions were run in triplicate, and the data were normalized to that of β-actin. Relative differences in PCR results were evaluated using the comparative cycle threshold method. Primer sets were: mouse NFATc1, 5′-CCGTTGCTTCCAGAAAATAACA-3′ (forward), 5′-TGTGGGATGTGAACTCGGAA-3′ (reverse); mouse β-actin, 5′-TCTGCTGGAAGGTGGACAGT-3′ (forward), 5′-CCTCTATGCCAACACAGTC-3′ (reverse); mouse TRAP 5′-CTGGAGTGCACGATG-CCAGCGACA-3′ (forward), 5′-TCCGTGCTCGGCGATGGACCAGA-3′ (reverse); zebrafish cathepsin K, 5′-CTATTAAAGAGATTCCTCAGGGTAAGCA-3′ (forward), 5′-ACACGGGTCCCACATTGG-3′ (reverse); zebrafish TRAP, 5′-CGTCCACTGACCACAGGAAGA-3′ (forward), 5′-AAGGA-TCCTGACGTCTGATTGA-3′ (reverse); zebrafish matrix metalloproteinase (MMP)-9, 5′-AAATCTGTGTTCGTGACGTT-TCCT-3′ (forward), 5′-GCCGTAACGCTT-CAGATACTCAT-3′ (reverse); zebrafish MMP2, 5′-TTGCTTCCCTGCAAACTTTTG-3′ (forward), 5′-GAGCCACTTCTTTGTCTGTGTGA-3′ (reverse); zebrafish alkaline phosphatase, 5′-CAGTGGGAATCGTCACAACAA-3′ (forward), 5′-CCACACAGTGGGCATAAGCA-3′ (reverse); zebrafish osterix, 5′-AAGAAACCTGTCCACAGCTG-3′ (forward), 5′-GAGGCTTTACCGTACACCTT-3′ (reverse); and zebrafish β-actin, 5′-CAACAGGGAAAAGATG-ACACAGAT-3′ (forward), 5′-CAGCCTGGATGGCAACGT-3′ (reverse).

Microcomputed tomography scanning *of z*ebrafish bone
-----------------------------------------------------

To measure zebrafish vertebrae density, fish were fixed in a stretched position on a sample holder and scanned with a microcomputed tomography (μ-CT) system (Siemens, USA). Experiments were performed on an animal Inveon system in the Ochang Center at the Korea Basic Science Institute. The μ-CT scanner was set to 80 kVp for the X-ray tube, 500 μA for the X-ray source, and 800-ms exposure time. The detector and Xray source were rotated 360° in 360 steps. The number of calibration exposures was 30. The system magnification was set to 102.55 mm axial field view and 30.74 mm transaxial field view. Data were analyzed using Inveon Research Workplace software (Siemens).

Measurement of calcium/phosphorus ratio in scales
-------------------------------------------------

To measure the calcium and phosphorus concentration in bones (vertebrae) and scales, we prepared the scales and vertebrae from each group, the scales were collected by forceps from each side of fish. The remaining body was taken off head and then treated 0.1% trypsin for 10 min at 37 to collect the vertebrae. The scales and vertebrae were washed 2 times with distilled water. Both samples were measured the weight after incubating in dry oven for overnight, and then the samples were measured by atomic absorption spectrometry. Calcium/phosphorus (Ca:P) ratios in samples were measured by inductively coupled plasma mass spectrometry (VG PlasmaQuad, Fisons Instruments, UK). All values were adjusted for minor deviations from standard calcium solutions with accepted natural ratios (the ratio of Ca:P is about 2:1). All samples were measured in duplicate ([@b23-molce-39-12-855]).

Statistical analysis
--------------------

Values are presented as mean ± standard deviation (SD) of three or more experiments. Data were analyzed using Student's *t*-test or one-way analysis of variance for comparisons between two mean values. A value of *P* \< 0.05 was considered significant.

RESULTS
=======

Inhibition effect of aqueous ginseng extract on RANKL-induced osteoclast differentiation in mouse BMMs
------------------------------------------------------------------------------------------------------

To test the effect of aqueous ginseng extract on osteoclast differentiation, cells were isolated from mice and incubated with the osteoclast-generating factors MCSF-1 and RANKL, with or without aqueous ginseng extract. After TRAP staining, TRAP-positive multinucleated cells were counted. Aqueous ginseng extracts dose-dependently diminished osteoclast differentiation ([Figs. 1A and 1B](#f1-molce-39-12-855){ref-type="fig"}) without toxicity up to 100 μg/ml ([Fig. 1B](#f1-molce-39-12-855){ref-type="fig"}). The same procedure was used to assay 14 types of ginsenosides at various concentrations. At 2.5 μM, ginsenosides Rd, Re, and compound K; and Fraction 11 inhibited osteoclast differentiation by \~60% ([Fig. 1C](#f1-molce-39-12-855){ref-type="fig"}). The ginsenoside Rd showed toxicity ([Fig. 1D](#f1-molce-39-12-855){ref-type="fig"}). Among individual ginsenosides, ginsenoside Re exhibited the most potent inhibition of osteoclast differentiation.

Effect of aqueous ginseng extract on zebrafish model
----------------------------------------------------

We investigated the effects of 30 days of limited feeding on our zebrafish model. Zebrafish vertebrae were examined *ex vivo* by μ-CT. The μ-CT images showed that our experimental conditions did not significantly affect the vertebrae ([Fig. 2A](#f2-molce-39-12-855){ref-type="fig"}). The Ca:P ratio was in the normal range (2:1) in control vertebrae samples compared with the samples treated with aqueous ginseng extract. In samples of scales, which are part of the fish skeleton, the Ca:P ratio was significantly decreased to 1.78:1. However, the Ca:P ratio was restored to 2.06:1 in samples treated with aqueous ginseng extract ([Fig. 2b](#f2-molce-39-12-855){ref-type="fig"}). We also found that the mRNA expression level of the osteoclast marker genes including *TRAP, MMP9,* and *MMP2* was diminished; in particular, the *TRAP* expression was much lower in aqueous ginseng extract-treated samples compared to the controls ([Fig. 2C](#f2-molce-39-12-855){ref-type="fig"}) To confirm these findings, we visualized zebrafish scales with TRAP staining to examine the inhibition of osteoclast differentiation. Based on the results, we concluded that treatment with aqueous ginseng extract decreased osteoclast differentiation activity. Compared with controls, TRAP signal intensity was lower in aqueous ginseng extract-treated samples ([Fig. 2D](#f2-molce-39-12-855){ref-type="fig"}).

Effect of ginsenoside Re on osteoclast differentiation
------------------------------------------------------

Ginsenoside Re is a major compound in aqueous ginseng extract ([@b13-molce-39-12-855]). To elucidate the effects of ginsenoside Re, it was applied to BMMs with RANKL (25 ng/ml) and MCSF (30 ng/ml) at indicated concentrations and times. Based on TRAP activity assays and positive-osteoclasts cell counting, ginsenoside Re dose-dependently inhibited osteoclast differentiation ([Figs. 3A--3C](#f3-molce-39-12-855){ref-type="fig"}). Additionally, mRNA levels of the osteoclast differentiation marker genes NFATc1 and TRAP decreased up to 50% in 2.5 days ([Figs. 3D and 3E](#f3-molce-39-12-855){ref-type="fig"}). These results were from tests using 5 μM ginsenoside Re, which did not affect cell viability ([Fig. 3f](#f3-molce-39-12-855){ref-type="fig"}).

Blocking effect of ginsenoside Re on RANKL-induced osteoclast differentiation signaling pathway
-----------------------------------------------------------------------------------------------

To explore the mechanisms by which ginsenoside Re inhibits osteoclast differentiation, we tested whether ginsenoside Re reduced protein levels of the transcription factors NFATc1 and c-Fos in BMMs stimulated with RANKL. The levels of the protein degradation control protein CYLD did not change with ginsenoside Re treatment ([Fig. 4A](#f4-molce-39-12-855){ref-type="fig"}). RANKL-induced differentiation of osteoclasts involves amplification of cell signaling mediated through mitogen-activated protein kinases and activation of downstream transcription factors such as NF-κB and NFATc1 ([@b24-molce-39-12-855]).

Next, we investigated the effects of ginsenoside Re on intracellular signaling pathways in RANKL-induced BMMs. RANKL treatment of BMMs for 5 min dramatically increased phosphorylation of extracellular signal-regulated *kinase (ERK);* this was inhibited by treatment with ginsenoside Re ([Figs. 4B and 4C](#f4-molce-39-12-855){ref-type="fig"}). RANKL-induced p38 and JNK activation was not influenced by ginsenoside Re in the same conditions ([Figs. 4B, 4D, and 4E](#f4-molce-39-12-855){ref-type="fig"}). And we further examined the effect of ginsenoside Re on NF-κB signaling pathway, which is another major signaling pathway in RANKL-induced osteoclast differentiation. The phosphorylation-dependent degradation of IκBα, a negative feedback regulator of NF-κB, is a key event in RANKL-induced osteoclast differentiation and it is the evidence of NF-κB activation ([@b2-molce-39-12-855]). Ginsenoside Re-treated BMMs exhibited significantly decreased the amounts of total IκBα level same as DMSO treated samples even though RANKL-induced phospho-IκBα level was remained slightly in ginsenoside Re treated samples ([Figs. 4F and 4G](#f4-molce-39-12-855){ref-type="fig"}). Thus, the inhibitory effects of ginsenoside Re on osteoclastogenesis were shown to be mediated by blocking via ERK signaling pathway, not NF-κB pathway.

Effect of ginsenoside Re on osteoclast differentiation in zebrafish scales
--------------------------------------------------------------------------

We investigated the effects of ginsenoside Re as a major component of aqueous ginseng extract ([Fig. 2](#f2-molce-39-12-855){ref-type="fig"}). Based on toxicity tests using 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays ([Fig. 3F](#f3-molce-39-12-855){ref-type="fig"}), we selected a concentration of 5 μM as the optimal concentration for the zebrafish scale model. To confirm that 5 μM ginsenoside Re was appropriate for treatment in our model, we treated fish embryos for 3 days with 0 to 10 μM ginsenoside Re. In toxicity tests with zebrafish embryos, the highest concentration (10 μM) showed little toxicity such as embryonic death or abnormal morphology (data not shown). We used TRAP assays to evaluate the efficiency of inhibition of osteoclast differentiation on fish scale samples from controls and fish treated with ginsenoside Re for 35 days. Control scales showed TRAP staining that was widely distributed in the central and lateral areas, but ginsenoside Re-treated scales showed a more narrow distribution of TRAP staining ([Fig. 5A](#f5-molce-39-12-855){ref-type="fig"}). TRAP intensity for ginsenoside Re-treated samples was only 0.37-fold compared to the controls ([Fig. 5B](#f5-molce-39-12-855){ref-type="fig"}). This result indicates that ginsenoside Re suppressed osteoclast generation by zebrafish scales. These observations were confirmed by the decreased expression of the osteoclast marker genes *TRAP* and *cathepsin K*; gene expression was decreased \~0.7--0.8 fold in ginsenoside Re-treated samples compared to the controls ([Figs. 5C and 5D](#f5-molce-39-12-855){ref-type="fig"}). Expression of the osteoblast marker genes *ALP* and *osterix*, however, was the same in the control and ginsenoside Re samples ([Figs. 5E and 5F](#f5-molce-39-12-855){ref-type="fig"}).

DISCUSSION
==========

Bone health depends on the balance between osteoblasts and osteoclasts. In this study, we found that aqueous ginseng extract negatively regulated osteoclastogenic activity, with both *in vitro* and *in vivo* evidence of the anti-osteoporotic effects of the extract. Aqueous ginseng extract effectively suppressed osteoclast differentiation in mouse BMMs and zebrafish scales. Low Ca:P ratios affects serum parathyroid hormone (PTH) concentration and increases bone resorption ([@b8-molce-39-12-855]). Even through the major bone system, the vertebrae were not changed much, the Ca:P ratio of the scales treated with aqueous ginseng extract was significantly increased calcium uptake to naturally acceptable ratio (2.06:1) compared with the control (1.79:1), which suggested that ginseng extracts have an effects on inhibition of bone resorption by osteoclast differentiation ([Fig. 2](#f2-molce-39-12-855){ref-type="fig"}).

Aqueous ginseng extract inhibited osteoclast differentiation without toxicity toward BMMs. Ginsenosides are reported to possess effects such as anti-oxidant, anti-cancer, anti-diabetic, anti-adipocyte, anti-osteoporotic, and sexual enhancement activities ([@b17-molce-39-12-855]). Our group previously reported that red ginseng combined with other herbal medicines regulates osteoporosis in ovariectomized rats ([@b9-molce-39-12-855]).

In this study, we report the efficacy of a single ginseng treatment for preventing bone resorption through suppression of osteoclast differentiation. Among the various ginsenosides, major ginsenoside in aqueous ginseng extract, ginsenoside Re treatment blocked osteoclast differentiation and RANKL-induced NFATc1 expression level as osteoclastogenesis key transcription factor without any cytotoxicity in mouse BMMs ([Fig. 3](#f3-molce-39-12-855){ref-type="fig"}). In addition, we observed that ginsenoside Re influenced osteoclast differentiation via inhibition of RANKL-induced signaling pathway. In particular, ginsenoside Re blocked signaling of ERK and, which is known mechanism of osteoclast differentiation ([Fig. 4](#f4-molce-39-12-855){ref-type="fig"}). And we applied effect of ginsenoside Re to *in vivo* system on osteoclast differentiation using zebrafish model.

Osteoclast differentiation was inhibited by ginsenoside Re and osteoclast marker genes were significantly decreased in samples treated with ginsenoside Re in zebrafish scales. Ginsenoside Re treatment decreased mRNA expression level of *TRAP* and *cathepsin K*, although it did not markedly affect expression of osteoblast marker genes ([Fig. 5](#f5-molce-39-12-855){ref-type="fig"})*.* These findings demonstrated that the zebrafish scale model was an experimental approach for testing the effects of ginseng extract or ginsenoside Re on osteoclast differentiation. Therefore, we suggest that ginseng extract and the major ginsenoside Re appear to have beneficial effects on bone health.
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![Aqueous ginseng extract inhibition of osteoclast differentiation, and effects of 14 ginsenosides on osteoclast differentiation. (A) Mouse BMMs were harvested and exposed for 3 days to RANKL (25 ng/ml) and M-CSF (10 ng/ml) with or without ginseng active compounds. TRAP staining was performed, and (B) TRAP activity was measured at λ = 405 nm. Data are expressed as the percentage of TRAP activity in ginseng extract treated cells compared to untreated cells (mean ± SEM, n = 3) in blue, with cell viability at the same ginseng concentration tested by MTT assay in red. (C) RANKL-induced BMMs were treated with 14 ginsenosides, and osteoclast differentiation was evaluated by TRAP activity measured at λ = 405 nm. Data are expressed as a percentage of TRAP activity of untreated cells (mean ± SEM, n = 3). The red line indicates 60% inhibition at 2.5 μM. More effective ginsenosides are indicated in red. (d) Summary of osteoclast-differentiation inhibition efficiency of 14 ginsenosides and cell viability by MTT assays. EC~50~, half-maximal effective concentration. IC~50~, half-maximal growth inhibition concentration. Scale bar, 100 μm.](molce-39-12-855f1){#f1-molce-39-12-855}

![Effect of aqueous ginseng extract on osteoporosis in the zebrafish scale model. (A) After treatment with aqueous ginseng extract (GE, 10 μg/ml) for 35 days, zebrafish were scanned by μ-CT to visualize vertebrae density. (B) Calcium/phosphorous ratios were measured in vertebrae and scales from zebrafish samples by inductively coupled plasma mass spectrometry. (C) RT-PCR was performed to determine the mRNA expression levels of osteoclast marker genes *TRAP, MMP9,* and *MMP2* of and *β-actin*. (D) Zebrafish scales were stained with TRAP. Scale bar, 100 μm.](molce-39-12-855f2){#f2-molce-39-12-855}

![Effect of ginsenoside Re on osteoclast differentiation. (A) Total osteoclast formation by BMMs treated with the indicated concentrations of ginsenoside Re. TRAP staining was performed after 3 days to show TRAP + multinucleated cells, which were rare in the concentration of 5 μM groups. 40x. (B) TRAP activity was measured at λ = 405 nm. Data are expressed as a percentage of the TRAP activity of untreated cells (means ± SEM, n = 3). (C) TRAP-positive cells were counted under the same conditions. (D, E) qPCR was performed to confirm the mRNA expression levels of *NFATc1* and *TRAP* genes. (F) Cell viability at the indicated concentration of ginsenoside Re was tested by MTT assay.](molce-39-12-855f3){#f3-molce-39-12-855}

![Inhibition of ERK and NF-κB pathways by ginsenoside Re in BMMs. (A) BMMs were treated with ginsenoside Re (0--10 μM) with M-CSF (30 ng/ml) and RANKL (25 ng/ml) for 2.5 days. Whole cell lysates were extracted for Western blotting using antibodies against NFATc1, c-Fos, and CYLD. (B, F) BMMs were treated with ginsenoside Re (10 μM) or control (DMSO) for the indicated times. Whole cell lysates were used for Western blotting with antibodies against p-ERK, ERK, p-p38, p38, p-JNK, JNK, p-IκBα, and IκBα. GAPDH was the reference protein. (C, D, E, and G) The intensities of p-ERK, p-p38, p-JNK and p- IκBα were measured by densitometer. \**P* \< 0.05 by one-way ANOVA.](molce-39-12-855f4){#f4-molce-39-12-855}

![Effect of ginsenoside Re on zebrafish scale osteoclasts. (A) Ginsenoside Re-treated zebrafish scales were stained with TRAP. Red box, magnified X200; arrow, TRAP-positive signal. (B) TRAP signal intensity was measured in lateral regions. Five randomly selected points were measured per treated scale. (C, D) qPCR was performed to determine the mRNA levels of the osteoclast markers *TRAP* and *cathepsin K* and (E, F) the osteoblasts markers *ALP* and *osterix*.\**P* \< 0.05 and \*\**P* \< 0.01 by student's *t*-test.](molce-39-12-855f5){#f5-molce-39-12-855}
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